만성 두드러기의 환자 자기 평가 도구로서 UAS7 사용 현황에 대한 고찰 : 국내외 연구논문 분석 및 일개 한방병원 의무기록을 중심으로
Trends of Using UAS7 in Chronic Urticaria Literature and Adherence of UAS7 in a Single Korean Medical Hospital
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives : The purpose of this study is to investigate the using trends of UAS7 over the last 5 years to analyze patients using UAS7 in a single Korean medicine hospital and to understand and suggest the actual status of application in clinical research. Methods : PubMed, RISS and OASIS were used to search clinical research papers related to chronic urticaria in the last 5 years. The adherence of UAS7 was assessed based on medical records in a single Korean medical hospital for 4 weeks. Results : Total 536 articles were selected, and 401(74.8%) articles used the assessment tool. UAS7 has been most commonly used assessment tool to evaluate the severity of chronic urticaria and DLQI has been most commonly used to evaluate the quality of life. The usage rate of UAS7 increased from 50% in 2016 to 85% in 2020. There were a total of 10 articles in traditional medicine research, of which 9 assessment tools were used and 4 articles used UAS7. To analyze adherence of UAS7, a total of 15 patients were selected. 6 patients (40%) did not record any value, and only 2 patients(13%) showed more than 80% adherence. Conclusions : UAS7 is most commonly used assessment tool in clinical research currently. However, since patient record adherence tends to be poor, it is needed to find ways increasing the UAS7 record adherence.
Abstract
Objectives : The purpose of this study is to investigate the using trends of UAS7 over the last 5 years to analyze patients using UAS7 in a single Korean medicine hospital and to understand and suggest the actual status of application in clinical research. Methods : PubMed, RISS and OASIS were used to search clinical research papers related to chronic urticaria in the last 5 years. The adherence of UAS7 was assessed based on medical records in a single Korean medical hospital for 4 weeks. Results : Total 536 articles were selected, and 401(74.8%) articles used the assessment tool. UAS7 has been most commonly used assessment tool to evaluate the severity of chronic urticaria and DLQI has been most commonly used to evaluate the quality of life. The usage rate of UAS7 increased from 50% in 2016 to 85% in 2020. There were a total of 10 articles in traditional medicine research, of which 9 assessment tools were used and 4 articles used UAS7. To analyze adherence of UAS7, a total of 15 patients were selected. 6 patients (40%) did not record any value, and only 2 patients(13%) showed more than 80% adherence. Conclusions : UAS7 is most commonly used assessment tool in clinical research currently. However, since patient record adherence tends to be poor, it is needed to find ways increasing the UAS7 record adherence.
참고문헌 (35)
- Maurer M, "Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report", Allergy, 66, pp.317~330 (2011)
- 이나미, "Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010-2014", Allergy, Asthma & Immunology Research, 9(5), pp.438~445 (2017), 대한천식알레르기학회
- Gaig P, "Epidemiology of urticaria in Spain", J Investig Allergol Clin Immunol, 14, pp.214~220 (2004)
- Kozel MM, "Natural course of physical and chronic urticaria and angioedema in 220 patients", J Am Acad Dermatol, 45, pp.387~391 (2001)
- Dias GA, "Impact of chronic urticaria on the quality of life of patients followed up at a university hospital", An Bras Dermatol, 91(6), pp.754~759 (2016)
- Hiragun M, "Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine", Allergy, 68(2), pp.229~235 (2013)
- Van der Valk PG, "The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre", Br J Dermatol, 146, pp.110~113 (2002)
- Kaplan AP, "Pathogenesis of chronic urticaria", Clin Exp Allergy, 39(6), pp.777~787 (2009)
- Maurer M, "The burden of chronic spontaneous urticaria is substantial : Real-world evidence from ASSURE-CSU", Allergy, 72(12), pp.2005~2016 (2017)
- Zuberbier T, "The EAACI", GA²LEN, WAO guideline for the definition, classification, diagnosis and management of urticaria, pp.Allergy, 2018[DOI]
- Młynek A, "How to assess disease activity in patients with chronic urticaria?", Allergy, 63(6), pp.777~780 (2008)
- Black N, "Patient reported outcome measures could help transform healthcare", BMJ, 346, pp.1~5 (2013)
- 최지숙, "의료의 질 향상을 위한 환자중심 건강결과 측정의 국제 동향과 국내 시사점 - OECD PaRIS를 중심으로", 한국의료질향상학회지, 25(1), pp.11~28 (2019), 한국의료질향상학회[DOI]
- Bae Y, "Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria", Allergol Int, 69(2), pp.304~306 (2020)
- Baiardini I, "Recommendations for assessing patientreported outcomes and health related quality of life in patients with urticaria : a GA2LEN taskforce position paper", Allergy, 66, pp.840~844 (2011)
- Baiardini I, "Clinically significant differences in patient-reported outcomes evaluations in chronic spontaneous urticaria", Curr Opin Allergy Clin Immunol, 20(3), pp.261~267 (2020)
- Hopkinson K, "The role of patient-reported outcomes in the management of chronic spontaneous urticaria", Br J Nurs, 28(3), pp.144~150 (2019)
- Moestrup K, "Patient-reported outcomes(PROs)in chronic urticaria", Int J Dermatol, 56(12), pp.1342~1348 (2017)
- 박소영, "다빈도 피부질환에 대한 국내외 한의학 논문에서 평가도구 사용현황에 대한 고찰", 한방안이비인후피부과학회지, 31(4), pp.31~41 (2018), 대한한방안이비인후피부과학회[DOI]
- Patruno C, "Four-week Urticaria Activity Score-7 as a Useful Patient-reported Outcome to Assess Chronic Spontaneous Urticaria : A Multicentre Study Evaluation of Adherence and Patients' Perspective", Acta Derm Venereol, 99(10), pp.903~904 (2019)
- Weller K, "The response to treatment in chronic spontaneous urticaria depends on how it is measured", J Allergy Clin Immunol Pract, 7(6), pp.2055~2056 (2019)
- Weller K, "Development and validation of the Urticaria Control Test : a patient-reported outcome instrument for assessing urticaria control", J Allergy Clin Immunol, 133(5), pp.1365~1372 (2014)
- 이지호, "Adaptation and Validation of the Korean Version of the Urticaria Control Test and Its Correlation With Salivary Cortisone", Allergy, Asthma & Immunology Research, 11(1), pp.55~67 (2019), 대한천식알레르기학회
- Patruno C, "Four-week Urticaria Activity Score-7 as a Useful Patient-reported Outcome to Assess Chronic Spontaneous Urticaria : A Multicentre Study Evaluation of Adherence and Patients' Perspective", Acta Derm Venereol, 99(10), pp.903~904 (2019)
- Huber LR, "Comparison of prospective daily diaries and retrospective recall to measure oral contraceptive adherence", Contraception, 88(4), pp.492~497 (2013)
- Gimenez-Arnau A, "A Specialized Therapeutic Approach to Chronic Urticaria Patient's Refractory to H1-Antihistamines Improves the Burden of the Disease", The Spanish AWARE Experience, 32(3), pp.1~27 (2020)
- Dekkers C, "Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients", Pediatr Allergy Immunol, 00, pp.1~7 (2021)
- Oliver ET, "Effects of an Oral CRTh2 Antagonist(AZD1981)on Eosinophil Activity and Symptoms in Chronic Spontaneous Urticaria", Int Arch Allergy Immunol, 179(1), pp.21~30 (2019)
- Ertas R, "The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change", Allergy, 73(3), pp.705~712 (2018)
- Zhang L, "Serum miR-125a-5p and CCL17Upregulated in Chronic Spontaneous Urticaria and Correlated with Treatment Response", Acta Derm Venereol, 99(6), pp.571~578 (2019)
- Maurer M, "Validity and responsiveness of the Urticaria Activity and Impact Measure : A new patient-reported tool", Ann Allergy Asthma Immunol, 120(6), pp.641~647 (2018)
- Kaliyadan F, "Use of Mobile Applications in Dermatology", Indian J Dermatol, 65(5), pp.371~376 (2020)
- 서진순, "아토피피부염 환자의 개인별 증상 기록에 대한 순응도 연구", 대한예방한의학회지, 24(2), pp.71~82 (2020), 대한예방한의학회[DOI]
- Rijsbergen M, "Mobile e-diary application facilitates the monitoring of patient-reported outcomes and a high treatment adherence for clinical trials in dermatology", J Eur Acad Dermatol Venereol, 34(3), pp.633~639 (2020)
- Hide M, "Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients : Subgroup analysis of the phase 3 POLARIS study", Allergol Int, 67(2), pp.243~252 (2018)
